Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice tradipitant (Nereus) Prior Auth Coverag…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PMN.307

    Clinical Policy: Tradipitant (Nereus)

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PMN.307 alerts

    Get alerted when Policy CP.PMN.307 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for coverage of tradipitant (Nereus) for prevention of motion-induced vomiting in adults across QualChoice lines of business.

    Policy Summary
    PayerQualChoice
    PolicyClinical Policy: Tradipitant (Nereus)
    Policy CodePolicy CP.PMN.307
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Next Review Date
    Key ActionSubmit clinical documentation (office notes, labs, or other information) demonstrating the member meets all approval criteria when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    85 mgavailable capsule strength
    170 mgmaximum daily dose
    ≤7 daysapproval duration / max supply
    ≥18minimum age
    90

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    max doses / year

    Coverage Criteria

    inv-01: Initial Therapy

    Covered when ALL of the following are met:

    Initial Therapy Criteria: 1. Prescribed for the prevention of motion-induced vomiting; 2. Age ≥ 18 years; 3. Member has a planned event expected to cause vomiting induced by motion; 4. Failure of transdermal scopolamine unless contraindicated or clinically significant adverse effects are experienced; 5. Failure of ≥ 2 antihistamines used for motion sickness (e.g., dimenhydrinate, meclizine, promethazine) unless clinically significant adverse effects or contraindications; 6. Request is for ≤ 7 days supply unless medical justification is provided; 7. Request is for ≤ 90 doses per 365-day period unless medical justification is provided; 8. Dose does not exceed 170 mg per 24-hour period.Dose ≤ 170 mg/24 hours; Supply ≤ 7 days; ≤ 90 doses/365 days

    Illinois HIM requests are exempt from step therapy requirements per IL HB 5395

    inv-02: Continuation Therapy

    Re-authorization is not permitted; members must meet the initial approval criteria for new requests.Not applicable

    Approval duration: Not applicable

    Non–FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the provider submits sufficient documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policies (for example, CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, or CP.PMN.53 for Medicaid) or applicable evidence of coverage documents.

    Initial Therapy

    inv-14: Initial Therapy

    Initial approval for motion sickness prevention requires all listed criteria.

    Initial Therapy: See coverage criteria: indication for prevention of motion-induced vomiting; age ≥ 18 years; planned event expected to cause vomiting induced by motion; failure of transdermal scopolamine unless contraindicated or adverse effects; failure of ≥ 2 antihistamines used for motion sickness (e.g., dimenhydrinate, meclizine, promethazine) unless contraindicated or adverse effects; request for ≤ 7 days supply unless medical justification provided; request for ≤ 90 doses per 365-day period unless medical justification provided; dose does not exceed 170 mg per 24-hour period.Dose ≤ 170 mg/24 hours; Supply ≤ 7 days; ≤ 90 doses/365 days

    Therapeutic alternatives listed in Appendix B; Illinois HIM requests exempt from step therapy per IL HB 5395

    Continuation / Re-authorization

    inv-15: Re-authorization

    Re-authorization is not permitted; members must meet initial approval criteria for each request.N/A

    Approval duration: Not applicable

    Provider Actions & Documentation

    Prior Authorization

    Prior authorization required; 7-day approval

    Prior authorization is required for tradipitant (Nereus) for motion sickness prevention. Approval duration is 7 days. Re-authorization is not permitted; members must meet the initial approval criteria for any subsequent request.

    • Approval duration: 7 days
    • Re-authorization is not permitted; members must meet initial approval criteria for subsequent requests.
    Step Therapy

    Step therapy: scopolamine then ≥2 antihistamines

    Prior to approval, the member must have failed transdermal scopolamine unless it is contraindicated or causes clinically significant adverse effects. The member must also have failed at least two antihistamines used for motion sickness (examples: dimenhydrinate, meclizine, promethazine) unless contraindicated or associated with clinically significant adverse effects. Illinois HIM requests are exempt from these step therapy requirements per IL HB 5395.

    • Failure of transdermal scopolamine required unless contraindicated or clinically significant adverse effects.

    Step Therapy Requirements

    StepRequirementNotes
    1Failure of transdermal scopolamine required prior to approval unless contraindicated or clinically significant adverse effects are experienced.Illinois HIM requests are exempt from step therapy requirements per IL HB 5395.
    StepRequirementNotes
    2Failure of ≥2 antihistamines used for motion sickness (e.g., dimenhydrinate, meclizine, promethazine) required prior to approval unless contraindicated or clinically significant adverse effects are experienced.Illinois HIM requests are exempt from step therapy requirements per IL HB 5395.

    Dosing, Age, and Supply Limits

    Maximum daily dose — 170 mg per 24-hour period
    Maximum daily dose170 mg per 24-hour period
    Dose description85 mg or 170 mg as single oral dose; max 170 mg/24-hour
    Capsule strength available85 mg per capsule
    Maximum supply per request — 7 days
    Maximum supply per request7 days
    Approval duration7 days (approval duration matches maximum supply)
    ExceptionLonger supply may be allowed with medical justification

    Quantity Limits

    inv-18: tradipitant (Nereus) — quantity limit 90
    Quantity limit (annual)90 doses per 365 days for tradipitant (Nereus)
    Dose form notedAvailable as 85 mg capsule; typical dosing 85 mg or 170 mg as single oral dose
    Use contextLimit applies to prevention of motion-induced vomiting in adults
    inv-19: tradipitant (Nereus) — maximum supply per request 7
    Maximum supply per request7 days for tradipitant (Nereus)
    Approval duration7 days per approval
    Supply exception

    Background

    Tradipitant (Nereus) is a substance P/neurokinin-1 (NK-1) receptor antagonist approved by the FDA for the prevention of vomiting induced by motion in adults. Labeled dosing includes single oral doses of 85 mg or 170 mg given approximately 60 minutes before an event expected to cause motion‑induced vomiting.

    Definitions

    inv-13: NK-1 receptor antagonist — Pharmacologic class: substance P/neurokinin-1 (NK-1) receptor antagonist (tradipitant).
    Pharmacologic classSubstance P/neurokinin-1 (NK-1) receptor antagonist
    Agent nameTradipitant (Nereus)
    Therapeutic roleApproved for prevention of vomiting induced by motion in adults
    Policy Summary
    PayerQualChoice
    PolicyClinical Policy: Tradipitant (Nereus)
    Policy CodePolicy CP.PMN.307
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Next Review Date
    Key ActionSubmit clinical documentation (office notes, labs, or other information) demonstrating the member meets all approval criteria when requesting prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation / Re-authorizationProvider Actions & DocumentationStep Therapy RequirementsDosing, Age, and Supply LimitsQuantity LimitsBackgroundDefinitions
  1. Failure of ≥2 antihistamines (e.g., dimenhydrinate, meclizine, promethazine) required unless contraindicated or clinically significant adverse effects.
  2. IL HIM requests exempt from step therapy per IL HB 5395.
  3. Documentation Required

    Include clinical documentation with PA request

    Submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results, or other clinical information, that demonstrates the member meets all approval criteria for motion sickness prevention.

    • Examples: office chart notes, lab results, or other clinical information showing planned event, prior therapy failures, age, and dosing/supply limits.
    Denial Risk

    Missing documentation may lead to denial

    Failure to provide the required documentation (office notes, laboratory results, or other clinical information) demonstrating that the approval criteria are met may result in denial of the request.

    • Missing documentation showing criteria (e.g., prior therapy failures, planned event, age) may lead to denial.
    Maximum annual doses — ≤ 90 doses per 365-day period
    Maximum annual doses≤ 90 doses per 365-day period
    ExceptionMore than 90 doses may be considered with medical justification
    Related supply limitRequests must also meet the ≤7 days per request requirement
    Minimum age — ≥ 18 years
    Minimum age for coverage≥ 18 years
    Indication age scopePolicy applies to adults for prevention of motion-induced vomiting
    Age verificationMember must be age 18 or older at time of request
    Longer supply may require medical justification